Why Insperity’s CEO Just Bought $4.7M of This Crushed HR Stock

NSP Stock 2026: Deep Value Recovery or Payroll Trap?

NYSE: NSP — $22.72 (-$0.36, -1.56%) as of Mar. 19, 2026, 4:10 PM ET

Insperity is not exactly a glamorous stock. It won’t dazzle you with robotaxis, space lasers, or AI agents promising to replace half the office before lunch. What it does instead is something much more grounded: it helps small and midsize businesses manage payroll, benefits, compliance, HR tech, onboarding, performance management, and the beautiful bureaucratic circus known as workforce administration.

In other words, Insperity sells order in a world that often resembles an Excel sheet on fire. 🔥📊

And right now, the market has decided this HR solutions provider deserves a seat in the penalty box. The stock has been crushed, profitability has taken real damage, and sentiment is somewhere between “meh” and “please make it stop.” Yet the CEO just bought $4.69 million worth of stock. The CFO bought too. The general counsel bought too. Directors joined the party. That’s not normal window dressing. That’s a corporate group project in confidence.

So let’s dig in.

1) The CEO’s $4.7M Cannonball 💼

When Paul J. Sarvadi, Insperity’s CEO and Chairman, buys 201,987 shares at $23.21, increasing his holdings by 16%, investors should pay attention. That is not a token “I support the team” purchase. That is a full-bodied cannonball into the pool.

What makes it even more interesting is the context. Sarvadi sold stock at $51.98 back in September 2025. Now he’s buying aggressively at less than half that level. That is one heck of a re-entry. If this were a dating story, we’d call it a dramatic reconciliation. ❤️📉

And he’s not alone. Just in March, the CFO, the general counsel, and a director all bought stock in the roughly $19 to $20.45 range. There were also multiple director buys in August and November 2025, though of course those earlier insiders are currently underwater. Insider timing is not infallible. But cluster buying at depressed prices usually means the people closest to the pain believe the market is overreacting.

2) What Went Wrong? Benefits Costs Ate the Room 🏥

Insperity’s recent numbers were rough. Fourth-quarter 2025 results were, to put it kindly, not a triumph of festive quarter-end joy.

• Q4 revenue rose 3% year over year to $1.7 billion

• Average paid worksite employees increased 1%

• Gross profit fell 21%

• Net loss came in at $33 million

• Adjusted EBITDA was negative $13 million

• Adjusted EPS landed at ($0.60)

That is not what investors want from a company whose entire existence revolves around helping other businesses manage people efficiently.

The culprit? Elevated benefits costs, driven by inpatient, outpatient, pharmacy trends, and high-cost claims activity. Translation: the healthcare math went feral. Insperity did increase pricing, but it wasn’t enough to fully offset the spike.

For full-year 2025, revenue still rose 4% to $6.8 billion, but the company posted a net loss of $7 million and adjusted EPS of just $1.03. So yes, the top line is moving, but the bottom line got hit by a benefits truck. 🚑

👉 Want the full picture? Dive into Insperity (NSP)'s financials here.

3) The Recovery Thesis: Margin First, Growth Later 🔧

Management insists 2025 was a transition year, not a collapse. Sarvadi said the company accomplished its key year-end objective with a “step up in gross profit margin,” positioning Insperity for a significant profit recovery in 2026.

That recovery is supposed to come from several levers:

• improved pricing

• better client selection

• changes to contract and plan design with UnitedHealthcare

• operating expense efficiency

• HR360 sales and retention initiatives

• the rollout of HRScale, which combines Insperity expertise with Workday technology

This is the key bull argument: 2025 was ugly, but 2026 could look meaningfully better if benefits costs normalize and the company executes properly.

Management’s guidance reflects that hope. For full-year 2026, adjusted EPS is expected in a range of $1.69 to $2.72, and adjusted EBITDA between $170 million and $230 million. That’s a large improvement range, though the wide band also tells you one thing clearly: visibility is not exactly crystal clear. 🔮

4) Valuation: The “Scary” P/E That Might Actually Be Cheap 🧮

On a trailing basis, NSP looks ridiculous. A 70x trailing P/E screams “please do not touch without adult supervision.”

But trailing earnings are distorted by the recent profitability collapse. On a forward basis, the stock trades at about 10.3x earnings, which is much more reasonable—arguably cheap—if management can actually deliver the rebound.

Other valuation stats also support the deep-value angle:

• Price/Sales: 0.13

• EV/Revenue: 0.09

• EV/EBITDA: 9.94

• PEG: 1.42

The PEG ratio suggests the stock is not outrageously mispriced relative to expected growth, but it’s hardly expensive if the recovery materializes. This is not a classic “cheap and wonderful” setup. It’s more like “cheap because management recently stepped on a rake.” The question is whether they’ve now stopped stepping on rakes.

5) Institutions Own the Place. Shorts Are Watching. 👀

Institutional ownership is absurdly high:

• 107.77% of shares outstanding

• 114.13% of float

• 367 institutions holding shares

BlackRock (which owns 14.19% of shares outstanding), Vanguard (10.74%), Bank of America, State Street, Goldman Sachs—plenty of major names are already involved. This doesn’t mean the stock can’t fall further. It does mean the float is tightly held, and if the turnaround gets traction, the move higher could be sharper than expected simply because the seat count is limited.

Short interest is notable too:

• 9.39% short

• 3.35 million shares short

• 2.47 days to cover 

That’s enough to show meaningful skepticism, but not enough to guarantee a face-ripping squeeze. The bears are present, but they’re not exactly storming the gates with flamethrowers. 🐻

🔍 For Insperity (NSP)'s Institutional Ownership breakdown, see here. 

6) The Dividend: Attractive… and Slightly Terrifying 💸

One reason value hunters may notice NSP is the dividend yield, which has ballooned as the stock collapsed. A double-digit yield looks tasty—until you remember the company just posted losses.

That is the core risk. If the rebound misses, the dividend starts looking less like “income” and more like “a pending board discussion.” Investors chasing yield here should understand they are also betting on profit recovery. No recovery, no comfort.

The FUNanc1al Take: HR Hero or Payroll Zero? 🤹

Insperity is a legitimate business in a real industry with sticky services, broad HR capabilities, and demand tied to small and midsize businesses needing help with a growing regulatory and benefits mess. This is not a fad company. It is not fake. It is just wounded.

The bull case:

• huge insider cluster buying

• forward P/E near 10

• potential 2026 margin recovery

• Workday-linked growth initiatives

• institutions heavily involved

The bear case:

• profits recently imploded

• healthcare costs remain unpredictable

• revenue growth is unimpressive

• dividend sustainability could become a real issue

• competition is fierce across payroll and PEO services

In short: this is not a sleep-well-at-night stock. It is a turnaround speculation with real upside if management is right.

⚡ Quick Take / TL;DR

Insperity looks like a classic damaged-but-not-dead stock.

✅ CEO just bought $4.7M of shares
✅ Insider cluster buying strengthens the signal
✅ Forward valuation looks cheap
✅ 2026 could bring meaningful margin recovery

But:

⚠️ Recent earnings were ugly
⚠️ Benefits costs remain the big wildcard
⚠️ The dividend may not be as safe as it looks
⚠️ This is a recovery bet, not a quality-compounder story right now

My take: interesting for a small starter position only. If you buy it, you’re betting on recovery—not current excellence.

❓ FAQ

Why did NSP stock crash so hard?
Because profitability got hammered by elevated healthcare benefit costs, leading to losses and a collapse in investor confidence.

Why does insider buying matter here?
Because the CEO’s purchase was massive, and it came alongside buys from the CFO, legal chief, and directors. That kind of cluster buying often signals conviction.

Is NSP cheap?
On trailing earnings, no. On forward earnings, yes—if the recovery actually happens.

Is this a short-squeeze candidate?
Not really. Short interest is meaningful but not extreme, and days to cover remain below 5.

What’s the biggest risk?
That benefits costs stay elevated, margin recovery disappoints, and the dividend gets pressured.

💡💡💡 Curious about another deep oil exploration play?
Check our take on UnitedHealth Group.

🌉 Food for Thought: The Cross-Hub Connection

NSP is:

💼 An HR story — compliance, payroll, workforce complexity
💸 A value story — crushed stock, cheap forward multiple, turnaround math
🧠 A psychology story — the market often confuses a brutal year with permanent decline
🏥 A healthcare cost story — one of the most important and least sexy forces in corporate profitability
⚙️ A business-model story — recurring service revenue can be powerful, until claims experience turns the spreadsheet into a horror film

👤 About Frédéric Marsanne

Frédéric Marsanne is the founder of FUNanc1al — part market analyst, part storyteller, part accidental comedian. A longtime investor, entrepreneur, and venture-builder across tech, biotech, and fintech, he now blends sharp insights with a twist of humor to help readers laugh, learn, live better lives, and invest a little wiser. When not decoding insider buys or poking fun at earnings calls, he’s building Cl1Q, writing fiction, painting, or discovering new passions to FUNalize.

🧾⚠️📢 Fun(anc1al) but Serious Disclaimer: 🧾⚠️📢

This article is for informational and entertainment purposes only and does not constitute financial advice. Turnaround stocks can stay broken longer than expected, dividends can shrink, and even CEOs with excellent timing are still allowed to be wrong. 

Investing in stocks involves real risk, including permanent capital loss. Always do your own research, size positions carefully, know your risk tolerance, and consult a licensed financial professional if you must.

Never mistake a charismatic CEO for a guarantee. And remember: a cheap stock is not the same thing as a safe stock.

Past performance is not indicative of future results. 
Resist FOMO and never invest money you can’t afford to lose. 

We laugh, we analyze, we meme.
We’re FUNanc1al — not financial advisors. 😄📉📈

Invest at your own risk. 🎢📉
Love at any pace. Laugh at every turn. 😄
Be Happy. 😄😄

🧭 Looking for a Different Angle?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny